Pancreatic Adenocarcinoma

P1, N=10, Recruiting, Northwell Health | Not yet recruiting --> Recruiting

P1, N=34, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Mar 2026 | Trial primary completion date: Dec 2026 --> Mar 2026

P=N/A, N=625, Recruiting, IRCCS San Raffaele | N=475 --> 625 | Trial completion date: Jun 2026 --> Jun 2030 | Trial primary completion date: Jun 2026 --> Dec 2026

Due to its rarity, PACC remains a diagnostic challenge. It has a better prognosis than PDAC; radical resection is recommended.

P1, N=694, Recruiting, AbbVie | N=512 --> 694 | Trial primary completion date: Jul 2026 --> Jul 2027

To this end, when applied to preoperative blood samples collected from a pilot cohort of 18 pancreas adenocarcinoma patients undergoing curative intent resection, K-MDS stratified these patients based on their risk of metastatic disease recurrence. This first-in-human experience with K-MDS suggests the assay has the potential to complement current commercial ctDNA assays for targeted detection of oncogenic mutations in patient whole blood.

P2, N=30, Active, not recruiting, University of Arizona | Trial completion date: Jan 2026 --> Jan 2027

P1, N=19, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027

TNS4 expression occurred more frequently among females and was observed when necrosis in tumor was strong. TNS2 and TNS3 are not involved in the development of ductal pancreatic adenocarcinoma.

P=N/A, N=60, Active, not recruiting, University of Oklahoma | Trial completion date: Dec 2024 --> Dec 2027

This case highlights the power of comprehensive molecular profiling and high-frequency ctDNA monitoring to capture tumor evolution and minimal residual disease. Importantly, it further demonstrates how MRD-guided surveillance enables a precise balance between fast-acting targeted therapy and the sustained effects of immunotherapy, providing a blueprint for individualized, context- driven treatment strategies in rare molecular subtypes of pancreatic cancer.

In a phase 1b trial (ARC-8), we evaluated safety and efficacy of quemliclustat combined with gemcitabine/nab-paclitaxel (G/nP) with or without zimberelimab (anti-programmed cell death protein 1 (PD-1)) in first-line metastatic pancreatic ductal adenocarcinoma (PDAC)...High tumor NR4A expression was associated with improved overall survival (OS) in ARC-8 but not in two external cohorts from the PRINCE (G/nP + nivolumab (nivo)) or Morpheus-PDAC (G/nP) trials...In paired pretreatment/posttreatment biopsies, maximal downregulation of NR4A expression was associated with T cell activation and improved OS, pointing to a biological link between tumor adenosine and clinical benefit. ClinicalTrials.gov identifier: NCT04104672 .